2021 TSOC共识路径：2型糖尿病的新疗法

2021-09-20 台湾心脏病学会 JACC: Asia

2021年9月，中国台湾心脏病学会颁布了2021年2型糖尿病（T2DM）新药物治疗共识路径。文章总结了近期新的临床研究证据，对T2DM患者的药物治疗路径提出推荐指导。

中文标题：

英文标题：

2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes

发布机构：

台湾心脏病学会

发布日期：

2021-09-20

简要介绍：

2021年9月，中国台湾心脏病学会颁布了2021年2型糖尿病（T2DM）新药物治疗共识路径。文章总结了近期新的临床研究证据，对T2DM患者的药物治疗路径提出推荐指导。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=c1c411c00228835b, title=2021 TSOC共识路径：2型糖尿病的新疗法, enTitle=2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes, guiderFrom=JACC: Asia, authorId=0, author=, summary=2021年9月，中国台湾心脏病学会颁布了2021年2型糖尿病（T2DM）新药物治疗共识路径。文章总结了近期新的临床研究证据，对T2DM患者的药物治疗路径提出推荐指导。, cover=https://img.medsci.cn/20211210/1639125315912_1608702.jpg, journalId=0, articlesId=null, associationId=267, associationName=台湾心脏病学会, associationIntro=null, copyright=0, guiderPublishedTime=Mon Sep 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年9月，中国台湾心脏病学会颁布了2021年2型糖尿病（T2DM）新药物治疗共识路径。文章总结了近期新的临床研究证据，对T2DM患者的药物治疗路径提出推荐指导。</span></p>, tagList=[TagDto(tagId=216, tagName=糖尿病), TagDto(tagId=2052, tagName=2型糖尿病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2052, guiderKeyword=2型糖尿病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=5, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3226, appHits=187, showAppHits=0, pcHits=388, showPcHits=3039, likes=1, shares=8, comments=22, approvalStatus=1, publishedTime=Fri Dec 10 16:47:09 CST 2021, publishedTimeString=2021-09-20, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Fri Dec 10 16:39:43 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Fri Jan 05 12:54:24 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 TSOC共识路径：2型糖尿病的新疗法.pdf)])

2021 TSOC共识路径：2型糖尿病的新疗法.pdf

下载请点击：

评论区 (17)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=2089535, encodeId=a29a2089535bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c46c5197630, createdName=1472d9b8m50暂无昵称, createdTime=Wed Sep 21 13:34:20 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194670, encodeId=166a11946e0db, content=好好看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Fri Feb 18 00:58:47 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180871, encodeId=f0ef11808e1c5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Wed Jan 05 14:40:05 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085333, encodeId=0d2c1085333f0, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Wed Dec 29 08:55:12 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085031, encodeId=b7bb108503114, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Tue Dec 28 09:54:24 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
2022-09-21 1472d9b8m50暂无昵称

学习了

83 0
[GetPortalCommentsPageByObjectIdResponse(id=2089535, encodeId=a29a2089535bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c46c5197630, createdName=1472d9b8m50暂无昵称, createdTime=Wed Sep 21 13:34:20 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194670, encodeId=166a11946e0db, content=好好看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Fri Feb 18 00:58:47 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180871, encodeId=f0ef11808e1c5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Wed Jan 05 14:40:05 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085333, encodeId=0d2c1085333f0, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Wed Dec 29 08:55:12 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085031, encodeId=b7bb108503114, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Tue Dec 28 09:54:24 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
2022-02-18 1351fc2f66m

好好看看

93 0
[GetPortalCommentsPageByObjectIdResponse(id=2089535, encodeId=a29a2089535bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c46c5197630, createdName=1472d9b8m50暂无昵称, createdTime=Wed Sep 21 13:34:20 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194670, encodeId=166a11946e0db, content=好好看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Fri Feb 18 00:58:47 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180871, encodeId=f0ef11808e1c5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Wed Jan 05 14:40:05 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085333, encodeId=0d2c1085333f0, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Wed Dec 29 08:55:12 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085031, encodeId=b7bb108503114, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Tue Dec 28 09:54:24 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
2022-01-05 坚定的心

学习了

96 0
[GetPortalCommentsPageByObjectIdResponse(id=2089535, encodeId=a29a2089535bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c46c5197630, createdName=1472d9b8m50暂无昵称, createdTime=Wed Sep 21 13:34:20 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194670, encodeId=166a11946e0db, content=好好看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Fri Feb 18 00:58:47 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180871, encodeId=f0ef11808e1c5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Wed Jan 05 14:40:05 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085333, encodeId=0d2c1085333f0, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Wed Dec 29 08:55:12 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085031, encodeId=b7bb108503114, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Tue Dec 28 09:54:24 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
2021-12-29 278103059

好好学习

108 0
[GetPortalCommentsPageByObjectIdResponse(id=2089535, encodeId=a29a2089535bf, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c46c5197630, createdName=1472d9b8m50暂无昵称, createdTime=Wed Sep 21 13:34:20 CST 2022, time=2022-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194670, encodeId=166a11946e0db, content=好好看看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=066c2128345, createdName=1351fc2f66m, createdTime=Fri Feb 18 00:58:47 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1180871, encodeId=f0ef11808e1c5, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210302/d7aef29f1c284560b978861e2a96fbb2/c495254e3ce54350a8a4f1eb91e884c8.jpg, createdBy=15e55464744, createdName=坚定的心, createdTime=Wed Jan 05 14:40:05 CST 2022, time=2022-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085333, encodeId=0d2c1085333f0, content=好好学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Wed Dec 29 08:55:12 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085031, encodeId=b7bb108503114, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Tue Dec 28 09:54:24 CST 2021, time=2021-12-28, status=1, ipAttribution=)]
2021-12-28 278103059

不错

113 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

内分泌指南

2021 TSOC共识路径：2型糖尿病的新疗法

相关指南

拓展阅读

科室

工具

服务